cbdMD (NYSEAMERICAN:YCBD) Stock Price Down 3.5% – Here’s What Happened

cbdMD, Inc. (NYSEAMERICAN:YCBD)’s stock price dropped 3.5% during trading on Friday . The stock traded as low as $0.7150 and last traded at $0.7235. Approximately 326,417 shares traded hands during trading, an increase of 55% from the average daily volume of 211,087 shares. The stock had previously closed at $0.75.

cbdMD Price Performance

The stock has a fifty day simple moving average of $0.79 and a two-hundred day simple moving average of $0.87.

cbdMD (NYSEAMERICAN:YCBD) last posted its earnings results on Thursday, May 14th. The company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.03). The firm had revenue of $5.64 million for the quarter, compared to analyst estimates of $5.29 million. cbdMD had a negative return on equity of 33.60% and a negative net margin of 13.29%.

Institutional Trading of cbdMD

An institutional investor recently bought a new position in cbdMD stock. Jane Street Group LLC bought a new position in shares of cbdMD, Inc. (NYSEAMERICAN:YCBD) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 51,141 shares of the company’s stock, valued at approximately $69,000. Jane Street Group LLC owned about 0.49% of cbdMD as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 7.18% of the company’s stock.

About cbdMD

cbdMD, Inc (NYSEAMERICAN: YCBD) is a Charlotte, North Carolina–based producer and distributor of hemp-derived cannabidiol (CBD) products. Since its founding in 2018, the company has focused on developing a diverse portfolio of wellness offerings designed for human and pet use. Its product range includes tinctures, capsules, gummies, topicals, and pet-specific formulations, each developed to comply with U.S. Food and Drug Administration (FDA) guidelines for hemp-derived substances.

The company operates a vertically integrated business model, sourcing U.S.-grown hemp and overseeing manufacturing processes in cGMP-certified facilities.